KAT5 and Alzheimer disease: However, under AD-like pathological conditions of augmented amyloidogenesis, APP induces a selective loss of CHCHD6 at the transcriptional level through binding of the AICD–Fe65–Tip60 complex to the CHCHD6 promoter.